The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1373
Peginterferon Alfa-2b (Sylatron) for Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved peginterferon alfa-2b (Sylatron – Merck) for adjuvant treatment of node-positive melanoma after surgical resection. Pegylated interferon has a longer duration of action than interferon alfa-2b (Intron A), which is also FDA-approved for adjuvant treatment of malignant melanoma after surgery, and can be given once a week, compared to 3-5 times a week for standard interferon.

A CLINICAL STUDY — Approval was based on an open-label study of 1256 patients with resected stage III melanoma who were randomized to observation alone or to treatment with peginterferon alfa-2b for up to 5 years. Median recurrence-free survival was significantly longer in the peginterferon group compared to the observation group (34.8 vs. 25.6 months). Overall survival, a secondary endpoint, was not significantly different between the two groups. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Peginterferon Alfa-2b (Sylatron) for Melanoma
Article code: 1373c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian